Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
NCT06292923Phase 2Active, not recruiting
- Sponsor
- Tiziana Life Sciences
- Start
- Nov 2023
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of foralumab in secondary-progressive multiple sclerosis (SPMS), sponsored by Tiziana Life Sciences. Started Nov 2023; status: active, not recruiting.
02
Drugs
foralumab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT06292923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06292923.